Highest-materiality recent filing
Amneal Q1 2026 net revenue $723M (+4% YoY), GAAP net income $62M, adj. diluted EPS $0.27
Net revenue $723M (+4% YoY); GAAP net income $62M vs. $12M in Q1 2025; diluted EPS $0.19.
Amneal acquires Kashiv BioSciences for $750M upfront; raises FY2026 guidance on strong Q1
Acquisition of Kashiv: $375M cash + $375M equity (28.9M shares) at close; up to $350M regulatory milestones plus royalties.
Amneal reports Q4 2025 net revenue $814M (+11% YoY); FY25 rev $3.02B; 2026 guidance $3.05-$3.15B
Q4 2025 net revenue $814M (+11% YoY); GAAP net income $35M; diluted EPS $0.11.
Amneal Pharmaceuticals makes effective opioid settlement with states and subdivisions
Amneal determined to make effective its Nationwide Opioids Settlement Agreement on Jan 29, 2026, with sufficient state and subdivision participation.
Amneal expects to meet or exceed FY2025 guidance; net leverage improves to 3.6x
Net revenue guidance $3.0B-$3.1B; Adj EBITDA $675M-$685M; Adj diluted EPS $0.75-$0.80.
Amneal Q3 revenue $785M (+12% YoY); GAAP EPS $0.01, adj. EPS $0.17; updated FY guidance
Net revenue $785M (+12% YoY); GAAP net income $2M vs loss of $0.2M; diluted EPS $0.01.
Amneal Q2: rev $725M (+3%), adj EBITDA $184M (+13%), raises FY25 guidance, refi debt
Q2 net revenue $725M, up 3% YoY; GAAP net income $22M vs $6M in Q2 2024.
Amneal completes $2.7B refinancing: $2.1B term loan and $600M notes
Borrowed $2.1B of new seven-year term B loans due Aug 2032; margin SOFR+3.50% or base+2.50%.
Amneal prices $600M 6.875% senior secured notes due 2032, upsizes term loan to $2.1B
$600M notes priced at par with 6.875% coupon, due 2032; downsized from $750M due to term loan increase.
Amneal seeks $1.8B new term loans and $750M notes to refinance debt
Amneal subsidiary seeks $1.8B in new seven-year term B loans to refinance existing term loans.
Amneal prelim Q2 revenue $720M-$730M, adj EBITDA $180M-$185M; director resigns
Net revenue $720M-$730M (+3% YoY); income before taxes $45M-$56M vs $20M in Q2 2024.
Amneal Q1 revenue $695M (+5% YoY), net income $12M vs loss, adj EPS $0.21 (+50%), reaffirms guidance
Net revenue $695M, up 5% YoY; GAAP net income $12M vs $92M loss in Q1 2024; diluted EPS $0.04 vs ($0.30).
Amneal reports Q4 revenue $731M (+18% YoY), FY24 revenue $2.79B (+17%); guides FY25 $3.0-3.1B
Q4 2024 GAAP net loss $31M ($0.10 diluted loss per share); adjusted net income $40M, adjusted EBITDA $155M.
Amneal expects to meet or exceed 2024 full-year guidance; net leverage ~4x
Expects to meet net revenue ($2.70-2.80B), adjusted EBITDA ($610-630M), and adjusted diluted EPS ($0.57-0.63).
Amneal Q3 net revenue up 13% to $702M; adjusted EBITDA $158M, guidance affirmed
Net revenue $702M (+13% YoY); GAAP net loss ~$0.2M vs prior year net income of $10M.
Amneal Q3 revenue up 13% to $702M; GAAP net loss $0.2M, adjusted EPS $0.16; affirms guidance
Revenue $702M (+13% YoY); adjusted EBITDA $158M (+2% YoY); adjusted diluted EPS $0.16 vs $0.19 YoY.
Amneal and Metsera partner on obesity drug portfolio; new India facilities cost $150-200M
Amneal to build two manufacturing facilities in India for peptide synthesis and sterile fill-finish; net cost $150-200M over 4-5 years.
Amneal beats Q2 estimates, raises FY guidance; FDA approves CREXONT for Parkinson's
Q2 net revenue $702M (+17% YoY); GAAP net income $6M ($0.02 diluted EPS).
Amneal Q1 revenue $659M (+18% YoY); GAAP net loss $92M on $94M opioid charge
Net revenue $659M (+18% YoY); Generics +14%, Specialty +15%, AvKARE +33%.
Amneal reports Q4 2023 net revenue $617M, GAAP loss $0.40 EPS; 2024 guidance $2.55-2.65B revenue
Q4 net revenue $617M (+1% YoY); GAAP net loss $99M ($0.40 loss per share); adjusted EBITDA $142M (-8% YoY).
Amneal refinances $2.13B term loans extending maturity to 2028; ABL facility upsized to $600M
Exchanged $2.13B of existing term loans due 2025 for new term loans due 2028; remaining $192M old loans unchanged.
Amneal completes UP-C elimination, new holding company becomes public issuer
Old Amneal became wholly-owned subsidiary of New Amneal; New Amneal renamed to Amneal Pharmaceuticals, Inc. and continues trading under AMRX.
Amneal Q3 net revenue $620M (+14% YoY); adjusted EBITDA $154M (+22%); guidance raised
Net revenue $620M (+14% YoY); GAAP net income $10M ($0.06 EPS) vs loss $0.02 in Q3 2022.
Amneal raises FY 2023 guidance after Q3 prelim: rev $610-620M, adj EBITDA $150-155M
Net revenue prelim Q3 2023 $610-620M, up ~13% YoY.
Amneal to eliminate Up-C structure, form NewCo; expects $30M annual tax-distribution savings
Binding term sheet executed Oct. 16, 2023 to reorganize into single-class structure via new Delaware holding company (NewCo).
Amneal Q2 revenue up 7% to $599M, net income $12M; raises 2023 guidance
Q2 net revenue $599M, +7% YoY; GAAP net income $12M vs loss $121M prior year.
Amneal Q1 revenue $558M (+12% YoY); adj. EBITDA $116M (+16%); reaffirms FY guidance
Net revenue $558M, up 12% YoY; driven by generics, specialty (Rytary, Unithroid), and AvKARE expansion.
Amneal reports preliminary Q1 2023 revenue $550-560M (+12% YoY); affirms FY guidance
Net revenue $550-560M, up ~12% YoY; loss before taxes $10M-$0 (improvement ~50%).
Amneal Q4 revenue $610M (+14% YoY), adj. EBITDA $154M; FY23 guidance $2.25-2.35B
Q4 2022 net revenue $610M (+14% YoY); GAAP net loss $4M ($0.03 loss per share).
Amneal Q3 2022 revenue $546M (+3.2% YoY), adj. EBITDA $126M, adj. EPS $0.14
Net revenue $546M, up 3.2% from $529M in Q3 2021; GAAP net loss $3M (diluted EPS $(0.02)).
Amneal Q2 2022: net loss $121M, revenue +5% to $559M; Opana settlement charge $263M
Q2 2022 net revenue $559M (+5% YoY); GAAP net loss $121M vs net income $15M in Q2 2021.
Amneal subsidiary settles Opana ER antitrust litigation for $265M; records Q2 charge
Impax subsidiary agrees to pay $265M plus interest to settle Opana ER antitrust class actions.
Amneal refinances $500M credit facility with new $350M revolving facility maturing 2027
New $350M senior secured revolving credit facility with Truist Bank as administrative agent; matures June 2, 2027.
Amneal reports Q1 2022 net revenue $498M (+1% YoY), GAAP net loss $2M, adj. EPS $0.12
Net revenue $498M vs $493M in Q1 2021; driven by generics and AvKARE distribution, partially offset by Zomig loss of exclusivity.
The Agreement provides that, as of the Effective Date, Mr. Daly will be employed as the Company’s Executive Vice President, Chief Legal Officer & Corporate Secretary at an annual base salary of $575,000.
On September 1, 2022, the Board of Directors (the “ Board ”) of Amneal Pharmaceuticals, Inc. (the “ Company ”) appointed Gustavo J. Pesquin as the Company’s Executive Vice President and Chief Commercial Officer – Specialty, effective September 6, 2022.
On July 29, 2022, the Board of Directors (the “ Board ”) of Amneal Pharmaceuticals, Inc. (the “ Company ”) appointed Deborah M. Autor to the Company’s Board.
On March 15, 2022, Joseph Todisco, Executive Vice President, Chief Commercial Officer – Specialty for Amneal Pharmaceuticals, Inc. (the “Company”), informed the Company of his decision to step down from his role to pursue another opportunity outside of the Company.
Max materiality 0.90 · Median 0.65 · Most common event earnings